R
Ralf Kohnen
Researcher at University of Erlangen-Nuremberg
Publications - 106
Citations - 7022
Ralf Kohnen is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Restless legs syndrome & Placebo. The author has an hindex of 48, co-authored 106 publications receiving 6670 citations.
Papers
More filters
Journal ArticleDOI
Identifying depression in primary care: a comparison of different methods in a prospective cohort study
TL;DR: The aim was to compare three different screening tools in order to evaluate which would be most appropriate for use in primary care, and to select three brief, self rating instruments.
Journal ArticleDOI
Parkinson's disease sleep scale—validation of the revised version PDSS-2
Claudia Trenkwalder,Ralf Kohnen,Birgit Högl,Vinod Metta,Friederike Sixel-Döring,Birgit Frauscher,Julia Hülsmann,Pablo Martinez-Martin,Kallol Ray Chaudhuri +8 more
TL;DR: The previous Parkinson's disease sleep scale (PDSS) is a 15‐item visual analogue scale that assesses the profile of nocturnal disturbances in Parkinson’s disease patients.
Journal ArticleDOI
L-Dopa Therapy of Uremic and Idiopathic Restless Legs Syndrome: A Double-Blind, Crossover Trial
C. Trenkwalder,K. Stiasny,T. Pollmächer,T. C. Wetter,Johannes Schwarz,Ralf Kohnen,J. Kazenwadel,Hans-Peter Krüger,S. Ramm,M. Künzel,Wolfgang H. Oertel +10 more
TL;DR: It is concluded that L-dopa 100-200 mg proved to be effective in idiopathic RLS and for the first time under controlled conditions in uremic R LS without any severe side effects.
Journal ArticleDOI
The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group.
Diego Garcia-Borreguero,Ralf Kohnen,Michael H. Silber,John W. Winkelman,John W. Winkelman,Christopher J. Earley,Christopher J. Earley,Birgit Högl,Mauro Manconi,Jacques Montplaisir,Yuichi Inoue,Richard P. Allen,Richard P. Allen +12 more
TL;DR: The use of either a dopamine-receptor agonist or α2δ calcium-channel ligand is recommended as the first-line treatment of RLS/WED for most patients, with the choice of agent dependent on the patient's severity of RLP symptoms, cognitive status, history, and comorbid conditions.
Journal ArticleDOI
Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
Diego Garcia-Borreguero,Richard P. Allen,Ralf Kohnen,Birgit Högl,Claudia Trenkwalder,Wolfgang H. Oertel,Wayne A. Hening,Walter Paulus,David B. Rye,Arthur S. Walters,Juliane Winkelmann +10 more
TL;DR: The Consensus Conference agreed upon new operational criteria for the clinical diagnosis of RLS augmentation: the MPI diagnostic criteria for augmentation.